Bone treatment after stopping denosumab for osteoporosis
Part of Bones, joints & muscles, Hormones & metabolism clinical trials.
This trial tests whether giving zoledronic acid (a bone-strengthening infusion) right after stopping denosumab can help prevent bone loss in women with post-menopausal osteoporosis. It may be a good option if you have finished at least 2 years of denosumab and your doctor says it's safe to stop.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman after menopause with osteoporosis.
- You have been taking denosumab for at least 2 years and your doctor has decided it's safe to stop because your bone density is stable and you haven't had new fractures.
- Before starting denosumab, you either had a severe fracture or a bone density score of -2.5 or lower in your spine or hip.
- You have not taken any other bone medications (like bisphosphonates, teriparatide, or romosozumab) in the last year.
- You do not have severe kidney disease or a known intolerance to zoledronic acid.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two medicines (ibandronate and zoledronic acid) to see which one works better at keeping bones strong after stopping denosumab (Prolia). It's for postmenopausal women with mild to moderate bone thinning.
This study tests an investigational injection called TST002 to see if it can help strengthen bones in postmenopausal women with osteoporosis or low bone mass. It may help reduce the risk of fractures.
This study compares two treatment plans for women with osteoporosis to see which one improves hip bone density more. Participants will either get two medications in sequence (romosozumab followed by denosumab) or one medication (zoledronic acid), both given as injections or infusions. The goal is to find a treatment that reduces fracture risk.
This trial tests if it's safe to switch from a long-term osteoporosis medication called Prolia to another treatment. It may help women and men who have been on Prolia for at least 3 years.
This Phase 2 study tests whether zoledronic acid or denosumab can prevent bone thinning in critically ill adults after staying in the ICU. It may help reduce the risk of future bone fractures if your body is at higher risk during and after critical illness.
This study looks at what medicine works best for women who have finished a 1-year course of a strong bone-building drug (romosozumab or teriparatide) for severe osteoporosis. The goal is to find a good follow-up treatment to keep bones strong and prevent fractures.
Hear when a new Postmenopausal Osteoporosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.